Amicus says on track for mid-year marketing application in EuropeThe company said, "We remain on track for a mid-year marketing application in Europe for migalastat monotherapy for Fabry disease and we look forward to an upcoming meeting with the FDA to discuss a path forward for an NDA submission for migalastat monotherapy in the United States. We continue to believe firmly that the totality of the data with this important new precision medicine-based therapy should be available to Fabry patients in the U.S. as soon as possible. Finally, advancing our next-generation enzyme replacement therapy for people living with Pompe disease is a key priority and that important program remains on track. Indeed, a busy and important set of activities are ahead for the Amicus team this year. We hope that success in these endeavors will enhance the lives of many people living with Fabry and Pompe diseases."

Argos Therapeutics hires Joan Winterbottom as Chief Human Resources OfficerArgos Therapeutics (ARGS) announced that Joan Winterbottom will join the company as chief human resources officer. Winterbottom most recently served as senior vice president of human resources at Amicus Therapeutics (FOLD).